title: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
abstract: The aim of this study was to determine the usefulness of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) following conventional chemotherapy for small cell lung cancer. 130 previously untreated patients were randomised to receive either r-metHuG-CSF (230 micrograms/m2) or placebo on days 4-17 following CDE (cyclophosphamide, doxorubicin and etoposide) chemotherapy. Over all cycles, 53% of 64 patients on placebo and only 26% of 65 patients on r-metHuG-CSF had at least one experience of neutropenia with fever defined as a neutrophil count less than 1.0 x 10(9)/l and a temperature > or = 38.2 degrees C (P < 0.002). It resulted in a reduction in the requirement for parenteral antibiotics from 58% in placebo patients compared with 37% in the r-metHuG-CSF group (P < 0.02), and a significant reduction in the incidence of infection-related hospitalisation. Chemotherapy doses were reduced by 15% or more at least once in 61% of the placebo group compared with 29% in the r-metHuG-CSF group (P < 0.001). 47% of the patients treated with placebo and 29% of the patients treated with r-metHuG-CSF experienced at least one cycle with a delay of 2 days or more in the administration of chemotherapy (P < 0.04). r-metHuG-CSF was well tolerated. There were no significant differences between the two groups in terms of response or survival.
authors.affiliation: Hopital Cardio-Vasculaire et Pneumologique Louis Pradel, Lyon, France.
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
authors.forename: J
authors.initials: J
authors.lastname: Green
authors.forename: C
authors.initials: C
authors.lastname: Manegold
authors.forename: J
authors.initials: J
authors.lastname: Von Pawel
authors.forename: U
authors.initials: U
authors.lastname: Gatzemeier
authors.forename: B
authors.initials: B
authors.lastname: Lebeau
authors.forename: A
authors.initials: A
authors.lastname: Depierre
authors.forename: P
authors.initials: P
authors.lastname: Johnson
authors.forename: G
authors.initials: G
authors.lastname: Decoster
authors.forename: D
authors.initials: D
authors.lastname: Tomita
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001424:Bacterial Infections / Q000517:prevention & control; D018288:Carcinoma, Small Cell / Q000628:therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide